ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford acquired 16,907 shares of ReWalk Robotics stock in a transaction on Friday, November 22nd. The shares were bought at an average cost of $1.83 per share, for a total transaction of $30,939.81. Following the completion of the transaction, the director now owns 43,418 shares in the company, valued at approximately $79,454.94. This trade represents a 63.77 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Michael Swinford also recently made the following trade(s):
- On Wednesday, November 20th, Michael Swinford purchased 16,471 shares of ReWalk Robotics stock. The shares were purchased at an average price of $1.84 per share, for a total transaction of $30,306.64.
ReWalk Robotics Stock Up 4.8 %
Shares of LFWD stock traded up $0.10 during trading hours on Tuesday, hitting $2.17. 7,947 shares of the company’s stock traded hands, compared to its average volume of 43,581. The stock’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $3.52. ReWalk Robotics Ltd. has a 12-month low of $1.70 and a 12-month high of $9.10. The stock has a market cap of $19.12 million, a price-to-earnings ratio of -0.83 and a beta of 2.07.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of ReWalk Robotics in a research report on Wednesday, November 13th.
Check Out Our Latest Analysis on LFWD
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new stake in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned about 0.16% of ReWalk Robotics at the end of the most recent quarter. Institutional investors own 26.76% of the company’s stock.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Recommended Stories
- Five stocks we like better than ReWalk Robotics
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- The How and Why of Investing in Gold Stocks
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- Trading Halts Explained
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.